PT2564846T - Processos para o tratamento de cancros hematológicos utilizando inibidores de pnf, tal como forodesina, em combinação com agentes anti-cd20 - Google Patents

Processos para o tratamento de cancros hematológicos utilizando inibidores de pnf, tal como forodesina, em combinação com agentes anti-cd20

Info

Publication number
PT2564846T
PT2564846T PT121772578T PT12177257T PT2564846T PT 2564846 T PT2564846 T PT 2564846T PT 121772578 T PT121772578 T PT 121772578T PT 12177257 T PT12177257 T PT 12177257T PT 2564846 T PT2564846 T PT 2564846T
Authority
PT
Portugal
Prior art keywords
forodesine
agents
methods
combination
hematologic cancers
Prior art date
Application number
PT121772578T
Other languages
English (en)
Inventor
Bantia Shanta
Breitfeld Philip
Sudhakara Babu Yarlagadda
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PT2564846T publication Critical patent/PT2564846T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT121772578T 2007-12-10 2008-12-10 Processos para o tratamento de cancros hematológicos utilizando inibidores de pnf, tal como forodesina, em combinação com agentes anti-cd20 PT2564846T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1276207P 2007-12-10 2007-12-10

Publications (1)

Publication Number Publication Date
PT2564846T true PT2564846T (pt) 2018-05-23

Family

ID=40431122

Family Applications (1)

Application Number Title Priority Date Filing Date
PT121772578T PT2564846T (pt) 2007-12-10 2008-12-10 Processos para o tratamento de cancros hematológicos utilizando inibidores de pnf, tal como forodesina, em combinação com agentes anti-cd20

Country Status (26)

Country Link
US (5) US20110038858A1 (pt)
EP (3) EP2237778A2 (pt)
JP (2) JP5543362B2 (pt)
KR (1) KR101545367B1 (pt)
CN (2) CN103736091B (pt)
AU (1) AU2008335167B2 (pt)
CA (2) CA2881035C (pt)
CY (1) CY1120203T1 (pt)
DK (1) DK2564846T3 (pt)
EA (2) EA018415B1 (pt)
ES (1) ES2670714T3 (pt)
GE (2) GEP20156288B (pt)
HR (1) HRP20180712T1 (pt)
HU (1) HUE037342T2 (pt)
IL (1) IL206264A (pt)
LT (1) LT2564846T (pt)
MY (2) MY163023A (pt)
NO (1) NO2564846T3 (pt)
NZ (3) NZ601072A (pt)
PH (1) PH12014501454A1 (pt)
PL (1) PL2564846T3 (pt)
PT (1) PT2564846T (pt)
SG (1) SG188870A1 (pt)
SI (1) SI2564846T1 (pt)
UA (2) UA104579C2 (pt)
WO (1) WO2009076455A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3010340A4 (en) 2013-06-22 2017-08-02 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
ES2909662T3 (es) * 2014-08-07 2022-05-09 Laevoroc Immunology Ag Composiciones que comprenden un inhibidor de PNP para uso en el tratamiento de la recaída de malignidad después de un trasplante de células madre hematopoyéticas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199697A (en) 1878-01-29 Improvement in butter-sharers
ES2106732T3 (es) 1989-02-27 1997-11-16 Biocryst Pharm Inc Desazaguaninas substituidas en 9 y no substituidas en 8.
US4985433A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US5008265A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PL319485A1 (en) * 1994-10-05 1997-08-04 Chiroscience Ltd Purinic and guanic compounds as pnp inhibitors
DK1616572T3 (da) * 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
US6387923B2 (en) * 2000-03-22 2002-05-14 Biocryst Pharmacueticals, Inc. Imminoribitol PNP inhibitors, preparation thereof and use thereof
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
CN103393681B (zh) * 2002-05-17 2017-04-12 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
US8003625B2 (en) * 2005-06-29 2011-08-23 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy

Also Published As

Publication number Publication date
PH12014501454B1 (en) 2016-01-18
GEP20135855B (en) 2013-06-25
EA201370055A1 (ru) 2013-11-29
IL206264A (en) 2017-04-30
JP2014094962A (ja) 2014-05-22
SI2564846T1 (en) 2018-06-29
KR20100101139A (ko) 2010-09-16
GEP20156288B (en) 2015-05-25
US11110092B2 (en) 2021-09-07
US20140178372A1 (en) 2014-06-26
CA2881035C (en) 2019-04-16
IL206264A0 (en) 2010-12-30
EP2564846B1 (en) 2018-02-28
CN103736091A (zh) 2014-04-23
PH12014501454A1 (en) 2016-01-18
NO2564846T3 (pt) 2018-07-28
HUE037342T2 (hu) 2018-08-28
NZ601072A (en) 2014-01-31
CN101969947A (zh) 2011-02-09
HRP20180712T1 (hr) 2018-06-15
JP5543362B2 (ja) 2014-07-09
US20190255058A1 (en) 2019-08-22
UA109571C2 (uk) 2015-09-10
AU2008335167A1 (en) 2009-06-18
CY1120203T1 (el) 2018-12-12
DK2564846T3 (en) 2018-05-22
CN103736091B (zh) 2016-09-28
NZ586416A (en) 2012-07-27
EP2237778A2 (en) 2010-10-13
EA025340B1 (ru) 2016-12-30
ES2670714T3 (es) 2018-05-31
US20240100055A1 (en) 2024-03-28
MY163023A (en) 2017-07-31
WO2009076455A2 (en) 2009-06-18
WO2009076455A3 (en) 2009-08-27
UA104579C2 (uk) 2014-02-25
CA2708606A1 (en) 2009-06-18
SG188870A1 (en) 2013-04-30
EA201070669A1 (ru) 2010-12-30
CN101969947B (zh) 2014-10-22
LT2564846T (lt) 2018-05-10
US20220040188A1 (en) 2022-02-10
PL2564846T3 (pl) 2018-08-31
EP2564846A1 (en) 2013-03-06
EA018415B1 (ru) 2013-07-30
CA2881035A1 (en) 2009-06-18
AU2008335167B2 (en) 2014-02-13
NZ617989A (en) 2015-05-29
KR101545367B1 (ko) 2015-08-18
US20110038858A1 (en) 2011-02-17
MY193789A (en) 2022-10-27
JP2011506345A (ja) 2011-03-03
CA2708606C (en) 2015-04-28
EP2581083A1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
IL257681A (en) Methods and compositions for the treatment of cancer
IL205682A0 (en) Amino triazoles as pi3k inhibitors
SI2429574T1 (sl) Sestavki in metode za zdravljenje hematoloških rakov, ki ciljajo interakcijo SIRP - CD47
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
EP2109687A4 (en) MICRO-RNA-BASED METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOUS LEUKEMIA (AML)
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
HRP20130642T1 (en) Methods and compositions for treating cancers
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL212544A0 (en) 7- hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
IL199881A0 (en) Compositions and methods for treating hematopietic malignancies
HRP20180712T1 (hr) Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20
HK1151971A1 (en) Compounds for use in the treatment of cancer
EP2291186A4 (en) MATERIALS AND METHODS FOR DELETING AND / OR TREATING NEUROFIBROMA AND ASSOCIATED TUMORS
EP2195650A4 (en) METHOD FOR THE TREATMENT OF TUMORS AT IMMUNRIVILEGED PLACES
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
AU2015201757A1 (en) Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL198070A (en) Sirna molecules for use in the treatment of damage are caused by ischemia